Artificial intelligence-assisted screening for NTRK fusion-positive salivary gland tumors: A novel digital pathology workflow.

However, the diagnostic complexity of the histological salivary gland cancer subtype and low NTRK fusion-positive salivary gland cancer incidence (5%), except for secretory carcinoma (90%), limit targeted therapy.

All 273 primary salivary gland tumors surgically obtained between 2005 and 2023 were retrospectively and blindly assessed using fluorescence in situ hybridization (FISH) for ETV6 rearrangements, pan-TRK immunohistochemistry (EPR17341), and differential diagnosis with Luigi-Oral for hematoxylin-eosin staining queries in December 2024 (https://luigi-pathology.com/).